Published in AIDS Res Hum Retroviruses on September 01, 2008
Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda, by use of next-generation deep sequencing. J Clin Microbiol (2011) 1.61
The rates of HIV superinfection and primary HIV incidence in a general population in Rakai, Uganda. J Infect Dis (2012) 1.49
Comparison of methods to detect HIV dual infection. AIDS Res Hum Retroviruses (2010) 1.47
Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol (2009) 1.28
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog (2013) 1.21
Frequency and implications of HIV superinfection. Lancet Infect Dis (2013) 1.19
HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS One (2009) 1.16
HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog (2012) 1.14
Clinical, virologic, and immunologic correlates of HIV-1 intraclade B dual infection among men who have sex with men. AIDS (2012) 1.10
Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses. Retrovirology (2012) 0.95
Cellular immune responses and susceptibility to HIV-1 superinfection: a case-control study. AIDS (2012) 0.94
Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology (2011) 0.93
HIV-1 superinfection is associated with an accelerated viral load increase but has a limited impact on disease progression. AIDS (2014) 0.92
Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses. J Clin Microbiol (2011) 0.90
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol (2013) 0.87
HIV-1 subtypes and recombinants in Northern Tanzania: distribution of viral quasispecies. PLoS One (2012) 0.87
The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection. PLoS Pathog (2015) 0.86
Macaque long-term nonprogressors resist superinfection with multiple CD8+ T cell escape variants of simian immunodeficiency virus. J Virol (2010) 0.85
Sang Froid in a time of trouble: is a vaccine against HIV possible? J Int AIDS Soc (2009) 0.81
Association between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection. J Virol (2014) 0.78
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. BMC Infect Dis (2013) 0.78
HIV-1 pol diversity among female bar and hotel workers in Northern Tanzania. PLoS One (2014) 0.77
HIV competition dynamics over sexual networks: first comer advantage conserves founder effects. PLoS Comput Biol (2015) 0.76
Retroviral vectors for analysis of viral mutagenesis and recombination. Viruses (2014) 0.76
Comprehensive Characterization of Humoral Correlates of Human Immunodeficiency Virus 1 Superinfection Acquisition in High-risk Kenyan Women. EBioMedicine (2017) 0.75
Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles. AIDS (2017) 0.75
Dual Infection Contributes to Rapid Disease Progression in Men Who Have Sex With Men in China. J Acquir Immune Defic Syndr (2017) 0.75
High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol (2000) 3.09
Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis (1998) 2.96
Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol (1999) 2.90
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
Incidence of HIV superinfection following primary infection. JAMA (2004) 1.92
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
HIV vaccine research: the way forward. Science (2008) 3.86
HIV/AIDS in women: an expanding epidemic. Science (2005) 3.68
Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS (2008) 3.42
HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality. J Infect Dis (2006) 3.09
Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol (2006) 2.95
HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis (2007) 2.87
Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses (2010) 2.86
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses (2002) 2.68
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis (2004) 2.45
Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS (2007) 2.44
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr (2007) 2.34
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children. Pediatr Infect Dis J (2004) 2.30
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr (2009) 2.26
Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women. J Infect Dis (2009) 2.24
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16
Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis (2003) 2.10
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS (2007) 1.99
Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96
Acute cytomegalovirus infection in Kenyan HIV-infected infants. AIDS (2009) 1.87
Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples. J Clin Microbiol (2002) 1.82
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis (2007) 1.75
Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis (2004) 1.74
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol (2003) 1.72
HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog (2012) 1.70
Association between cervical shedding of herpes simplex virus and HIV-1. AIDS (2002) 1.64
Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS (2012) 1.64
Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis (2004) 1.61
Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med (2008) 1.60
HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis (2009) 1.57
HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. AIDS (2015) 1.55
Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS (2004) 1.55
Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res (2003) 1.52
A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med (2011) 1.51
Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification. MBio (2013) 1.50
No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res Hum Retroviruses (2005) 1.47
Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis (2003) 1.36
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS (2008) 1.36
Basic statistical considerations in virological experiments. J Virol (2005) 1.32
The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS (2004) 1.32
Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. J Infect Dis (2004) 1.31
Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol (2005) 1.28
Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS (2007) 1.28
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS (2005) 1.27
Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol (2009) 1.24
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis (2010) 1.22
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog (2013) 1.21
Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retroviruses (2006) 1.21
Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res (2007) 1.19
Virus load during primary Human Immunodeficiency Virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis (2002) 1.19
Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS (2004) 1.19
Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters. J Clin Microbiol (2006) 1.17
A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A. J Virol (2006) 1.17
Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis (2004) 1.16
Subtype C Is associated with increased vaginal shedding of HIV-1. J Infect Dis (2005) 1.14
Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. J Acquir Immune Defic Syndr (2009) 1.14
HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog (2012) 1.14
The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol (2011) 1.13
Micronutrient supplementation increases genital tract shedding of HIV-1 in women: results of a randomized trial. J Acquir Immune Defic Syndr (2004) 1.12
HIV-1 superinfection and its implications for vaccine design. Curr HIV Res (2010) 1.11
HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS (2009) 1.11
Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women. AIDS (2004) 1.11
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses (2006) 1.09
Genital Inflammation Predicts HIV-1 Shedding Independent of Plasma Viral Load and Systemic Inflammation. J Acquir Immune Defic Syndr (2012) 1.09
A decrease in albumin in early HIV type 1 infection predicts subsequent disease progression. AIDS Res Hum Retroviruses (2007) 1.08
Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort. J Acquir Immune Defic Syndr (2005) 1.06
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial. J Infect Dis (2011) 1.05
Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial. Antivir Ther (2008) 1.04
Human herpesvirus 8: seroprevalence and correlates in prostitutes in Mombasa, Kenya. J Infect Dis (2003) 1.03
Illness during pregnancy and bacterial vaginosis are associated with in-utero HIV-1 transmission. AIDS (2010) 1.03
Risk factors for human immunodeficiency virus type-1 acquisition in women in Africa. J Neurovirol (2005) 1.03
Evaluation of a single round polymerase chain reaction assay using dried blood spots for diagnosis of HIV-1 infection in infants in an African setting. BMC Pediatr (2011) 1.01
Low serum albumin and the acute phase response predict low serum selenium in HIV-1 infected women. BMC Infect Dis (2006) 1.00
Sequence variability of the integrase protein from a diverse collection of HIV type 1 isolates representing several subtypes. AIDS Res Hum Retroviruses (2002) 1.00
Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment. J Acquir Immune Defic Syndr (2012) 1.00
A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. J Virol (2012) 1.00
Acute HIV infection among Kenyan infants. Clin Infect Dis (2008) 0.99
Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance. PLoS Med (2009) 0.99
Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS (2010) 0.99
Incidence and correlates of HIV-1 RNA detection in the breast milk of women receiving HAART for the prevention of HIV-1 transmission. PLoS One (2012) 0.98
Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA. J Acquir Immune Defic Syndr (2012) 0.97
Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses. J Virol (2008) 0.96
Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells. J Virol (2011) 0.96
Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. Virology (2010) 0.95